secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-218611
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech reports Q2 net loss of $18.5M; cash $170.1M to fund data readouts into mid-2024
--------------------------------------------------------------------------------

- Net loss $18.5M for Q2 2022 vs $38.4M in Q2 2021, driven by higher R&D and G&A costs.
- R&D expenses $12.2M (up from $6.7M) due to Phase 3 trial initiation and increased headcount.
- Cash and equivalents $170.1M at June 30, 2022, down from $211.5M at Dec 31, 2021.
- Initiated Phase 3 IOB-013/KN-D18 trial of IO102-IO103 + pembrolizumab in advanced melanoma.
- Phase 2 basket trial (IOB-022/KN-D38) dosing started; preliminary data expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/0001193125-22-218611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/d359264d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-218611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer